Literature DB >> 22783389

The expression levels of CD44v6 are correlated with the invasiveness of hepatocellular carcinoma in vitro, but do not appear to be clinically significant.

Kosuke Mima1, Hirohisa Okabe, Takatsugu Ishimoto, Hiromitsu Hayashi, Shigeki Nakagawa, Hideyuki Kuroki, Keisuke Miyake, Hiroshi Takamori, Toru Beppu, Hideo Baba.   

Abstract

The finding that the expression of a variant isoform of CD44 induced a metastatic phenotype in locally growing tumor cells has attracted considerable attention. A number of studies have analyzed the expression of CD44v6 in human tumors of different origins. However, the findings of these studies have been controversial. Therefore, in the present study, we assessed the association between CD44v6 expression and the invasive capacity of hepatocellular carcinoma (HCC) cell lines and also investigated the clinical significance of CD44v6 in 150 HCC patients by immunohistochemical analysis. The HCC cell lines with a high CD44v6 expression, including HLF, HLE and SK HEP-1, showed high invasive potential, whereas those with a low CD44v6 expression, including PLC/PRF/5 and HuH1, showed low invasiveness. Despite these observations, we did not find any significant correlation between CD44v6 expression and clinicopathological factors in patients. By contrast, there was a weak correlation between a low CD44v6 expression and vascular invasion in HCC patients (P=0.080). Kaplan-Meier curves revealed that a high CD44v6 expression was not significantly associated with disease-free survival (P=0.736) or overall survival (P=0.736). Our study suggests that the expression levels of CD44v6 are correlated with the invasiveness of HCC in vitro, but do not appear to be clinically significant. Future experiments should investigate the role of the various CD44 isoforms, including the CD44 standard isoform, in HCC cell lines and in patients with HCC.

Entities:  

Year:  2012        PMID: 22783389      PMCID: PMC3389621          DOI: 10.3892/ol.2012.611

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

Review 1.  CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value.

Authors:  V J Wielenga; R van der Neut; G J Offerhaus; S T Pals
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

4.  Epithelial-mesenchymal transitions and hepatocarcinogenesis.

Authors:  Janice Jou; Anna Mae Diehl
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

Review 5.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

6.  Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma.

Authors:  S Eguchi; T Kanematsu; S Arii; M Omata; M Kudo; M Sakamoto; K Takayasu; M Makuuchi; Y Matsuyama; M Monden
Journal:  Br J Surg       Date:  2011-01-25       Impact factor: 6.939

7.  Expression of CD44 is repressed in neuroblastoma cells.

Authors:  E Shtivelman; J M Bishop
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

Review 8.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

9.  CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor.

Authors:  R Stauder; W Eisterer; J Thaler; U Günthert
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

10.  Prognostic value of CD44 splice variants in human stage III cervical cancer.

Authors:  C Kainz; P Kohlberger; C Tempfer; G Sliutz; G Gitsch; A Reinthaller; G Breitenecker
Journal:  Eur J Cancer       Date:  1995-09       Impact factor: 9.162

View more
  4 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  CD44v6 expression in human skin keratinocytes as a possible mechanism for carcinogenesis associated with chronic arsenic exposure.

Authors:  S Huang; S Guo; F Guo; Q Yang; X Xiao; M Murata; S Ohnishi; S Kawanishi; N Ma
Journal:  Eur J Histochem       Date:  2013-01-14       Impact factor: 3.188

3.  CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma.

Authors:  Anna Kakehashi; Naomi Ishii; Eiji Sugihara; Min Gi; Hideyuki Saya; Hideki Wanibuchi
Journal:  Cancer Sci       Date:  2016-03-28       Impact factor: 6.716

4.  Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis.

Authors:  Yangkun Luo; Yan Tan
Journal:  Cancer Cell Int       Date:  2016-06-17       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.